Business · 12/12/2017Updated: 10/17/2026 · 1 min read
FDA Submits Information Collection for Orphan Drug Designation Review
Summary
The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, related to the review of orphan product designations, as part of the Paperwork Reduction Act of 1995.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →